Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340704 · ClinicalTrials.gov registry record · Phase 2
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
A Phase 2 study of Bladder, Neurogenic, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
- 20
- Study locations
NCT00340704 is a Phase 2 study of Bladder, Neurogenic that has completed, run by Boehringer Ingelheim. The registered enrollment target is 143 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT00340704, a Phase 2 study of Bladder, Neurogenic, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
- 20
- Study locations
Study Summary
Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.
Conditions Studied
Interventions
- DRUG tamsulosin hydrochloride
Study Locations (20)
New York
- - Buffalo
- - Lake Success
- - Tarrytown
Florida
- - Jacksonville
- - Tampa
Texas
- - Dallas
- - Houston
Alabama
- - Birmingham
California
- - Los Angeles
Illinois
- - Springfield
Indiana
- - Indianapolis
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00340704
The ClinicalTrials.gov registry entry for NCT00340704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder, Neurogenic appearing as the primary indexed condition, and to 1 intervention - of which tamsulosin hydrochloride is the first listed.
NCT00340704 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00340704 about?
NCT00340704 is a clinical study titled "PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder". Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.
What is the current status of trial NCT00340704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2006-04. Estimated completion is 2009-06.
What conditions does trial NCT00340704 study?
This clinical trial studies the following conditions: Bladder, Neurogenic.
What interventions are being tested in trial NCT00340704?
The interventions under investigation include: tamsulosin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00340704?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00340704 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder, Neurogenic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.